Nutriband receives USPTO Notice of Allowance for Aversa abuse deterrent patent

NutriBand Inc.

Notice of Allowance received Feb 3, 2025 for patent app 18/369,241 covering Aversa abuse deterrent transdermal systems.
US patent expected to issue after administrative processes; expands US IP protection for abuse deterrent transdermal portfolio.
Lead product Aversa Fentanyl could become first abuse-deterrent opioid patch; potential peak US sales $80-200M per Health Advances.
Aversa technology already protected by patents in 46 countries including US, Europe, Japan, China, Canada, Mexico, Australia.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.